ArticleEuropean respiratory review : an official journal of the European Respiratory Society2022
The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic.
Article in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Real-World Effectiveness of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Molecular epidemiology and resistance mechanisms of carbapenem-resistant Gram-negative bacilli in a referral hospital in Lima, Peru.JAC-antimicrobial resistance · 2026Article
- Fluoroquinolone-Free Prophylaxis and Impact on Bacterial Infections, Resistance, and Survival in Allo-HSCT: 5-Year Follow-up of the BATMO Protocol (Best Anti-microbical Therapy Trapianto di Midollo Osseo).Open forum infectious diseases · 2026Article
- Antimicrobial Resistance in Six Priority Bacteria in Italy: Trends and Regional Variation, 2015-2024.Antibiotics (Basel, Switzerland) · 2026Article
- Mobilome-driven antimicrobial resistance in a one health context: evidence and lessons from Africa.Frontiers in veterinary science · 2026Review
- Antibiogram of pathogenic bacterial isolates from various samples in Prince Sultan Hospital, Western Region, Saudi Arabia. Retrospective study from 2020 to 2024.Frontiers in antibiotics · 2026Article
- Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Association between early prophylactic heparin therapy and mortality in patients with septic shock secondary to respiratory infections: analysis based on MIMIC-IV database.BMC infectious diseases · 2025Article
- Effect of 1,3,4-oxadiazoles on expression of biofilm-associated bap gene in clinical isolates of multidrug-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Clinical Features of Multidrug-Resistant Gram-Negative Bacteremia: A Comparative Study of Cancer and Non-Cancer Patients.Microorganisms · 2025Article
- "Dusting Off the Cobwebs": Rethinking How We Use New Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multiplex PCR Pneumonia Panel in Critically Ill Patients Did Not Modify Mortality: A Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Economic burden of antimicrobial resistance on patients in Pakistan.Frontiers in public health · 2025Article
- Mechanisms of Polymyxin Resistance in Acid-Adapted EnteroinvasiveMicroorganisms · 2024Article
- Association between 25-hydroxy vitamin D, interleukin-4, and interferon-γ levels and asthma in children with Mycoplasma pneumonia infection.Scientific reports · 2024Article
- Assessment of Antibiotic Resistance in Pediatric Infections: A Romanian Case Study on Pathogen Prevalence and Effective Treatments.Antibiotics (Basel, Switzerland) · 2024Article
- An overview on pharmacological significance, phytochemical potential, traditional importance and conservation strategies ofHeliyon · 2024Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is recognised as a global threat to human health by national healthcare agencies, governments and medical societies, as well as the World Health Organization. Increasing resistance to available antimicrobial agents is of concern for bacterial, fungal, viral and parasitic pathogens. One of the greatest concerns is the continuing escalation of antimicrobial resistance among Gram-negative bacteria resulting in the endemic presence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) pathogens. This concern is heightened by the identification of such MDR/XDR Gram-negative bacteria in water and food sources, as colonisers of the intestine and other locations in both hospitalised patients and individuals in the community, and as agents of all types of infections. Pneumonia and other types of respiratory infections are among the most common infections caused by MDR/XDR Gram-negative bacteria and are associated with high rates of mortality. Future concerns are already heightened due to emergence of resistance to all existing antimicrobial agents developed in the past decade to treat MDR/XDR Gram-negative bacteria and a scarcity of novel agents in the developmental pipeline. This clinical scenario increases the likelihood of a future pandemic caused by MDR/XDR Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.